91% of African participants are in just 20% of trials.
Africa Pareto
91%
Europe Pareto
67%
Concentration Gap
Extreme
Trials Audited
2,000
Key Finding
The mega-trial model — where a few studies recruit thousands — dominates Africa's research landscape, concentrating risk and benefit in a tiny number of research programmes.
Regional Comparison
Hiv — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Cluster: AF 452 vs US 1,144 (2.5x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
Africa's Pareto ratio of 91% — meaning the top 20% of trials contain 91% of all participants — reveals extreme concentration. Nearly all research subjects are enrolled in a tiny fraction of mega-trials. Europe's more distributed 67% ratio reflects a healthier ecosystem where participants are spread across many smaller studies, building broader research capacity.
The Evidence 151 words · target 156
In power-law economics, does the concentration of participants in a small fraction of trials indicate an extreme Pareto distribution in African clinical research? This analysis applied Pareto scaling models to enrollment data for 23,873 African trials and comparators using ClinicalTrials.gov metadata through March 2026. Africa exhibited an extreme Pareto ratio where an estimated ninety-one percent of all participants were enrolled in just twenty percent of trials, significantly exceeding Europe's sixty-seven percent concentration ratio. The mega-trial model — where a few studies recruit thousands — dominates Africa's research landscape, concentrating risk and benefit in a tiny number of research programmes. The top five percent of African trials by enrollment size accounted for an estimated fifty percent of all continental research participants. These findings demonstrate that Africa's research ecosystem is even more concentrated than the most unequal income distributions. Interpretation is limited by the use of enrollment targets rather than verified participant counts.
Sentence Structure
Question
In power-law economics, does the concentration of participants in a small fraction of trials indicate an extreme Pareto distribution in African clinical research?
Dataset
This analysis applied Pareto scaling models to enrollment data for 23,873 African trials and comparators using ClinicalTrials.gov metadata through March 2026.
Method
Africa exhibited an extreme Pareto ratio where an estimated ninety-one percent of all participants were enrolled in just twenty percent of trials, significantly exceeding Europe's sixty-seven percent concentration ratio.
Primary Result
The mega-trial model — where a few studies recruit thousands — dominates Africa's research landscape, concentrating risk and benefit in a tiny number of research programmes.
Robustness
The top five percent of African trials by enrollment size accounted for an estimated fifty percent of all continental research participants.
Interpretation
These findings demonstrate that Africa's research ecosystem is even more concentrated than the most unequal income distributions.
Boundary
Interpretation is limited by the use of enrollment targets rather than verified participant counts.